CHMP positive recommendation for Avzivi ( bevacizumab biosimilar)
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Avzivi, intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix
The applicant for this medicinal product is FGK Representative Service GmbH.
Avzivi will be available as 25 mg/ml concentrate for solution for infusion. The active substance of Avzivi is bevacizumab, a monoclonal antibody (ATC code: L01FG01) which binds to the vascular endothelial growth factor (VEGF), thereby inhibiting the binding of VEGF to its receptors on the surface of endothelial cells. Neutralising the biological activity of VEGF, regresses the vascularisation of tumours, normalises the remaining tumour vasculature and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
Avzivi is a biosimilar medicinal product. It is highly similar to the reference product Avastin (bevacizumab), which was authorised in the EU on 12 January 2005. Data show that Avzivi has comparable quality, safety and efficacy to Avastin (bevacizumab).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins